Treatment(s) now being considered-Chemotherapy Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Chemotherapy Posts on Medivizor

Comparing different chemotherapy combinations to improve treatment of extensive-stage small cell lung cancer

Posted by on Sep 28, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at a combination of irinotecan (Camptosar) and platinum-based drugs, for treating patients with extensive-stage small cell lung cancer. The authors concluded that this combination has the potential to improve the outcomes for these patients.   Some background Extensive stage small-cell lung cancer (ES-SCLC) is...

Read More

Which chemotherapy drugs are better after surgery for patients with NSCLC?

Posted by on Sep 28, 2018 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fluorouracil (Adrucil) chemotherapy after surgery in patients with non-small-cell lung cancer (NSCLC). The authors concluded that treatment with fluorouracil resulted in prolonged recurrence-free survival compared to standard chemotherapy regimens. Some background Adjuvant therapy is given in...

Read More

Chemoradiation and hypothyroidism in patients with Hodgkin Lymphoma.

Posted by on Sep 15, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the development of hypothyroidism in patients with Hodgkin lymphoma after chemoradiation therapy. Patients were more likely to develop hypothyroidism after intensity modulated radiation therapy than after 3-dimensional conformal radiation therapy. Some background Patients with Hodgkin lymphoma (HL) are commonly...

Read More

Looking for patients with triple negative inoperable breast cancer to test a new treatment option atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) when used with chemotherapy in patients with inoperable, recurrent triple-negative breast cancer. The main outcome to be measured will be the overall survival (time from treatment until death from any cause) of participants.  The...

Read More

Looking for patients with triple negative breast cancer to test atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Post-surgery chemotherapy in early rectal cancer is associated with improved outcomes

Posted by on Aug 17, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the safety of localized surgery followed by chemotherapy compared with total mesorectal excision (TME; bowel and lymph nodes around the tumor are removed) in early stages (T0 to T1) of rectal cancer. Researchers suggested that local surgery followed by chemotherapy improves long term outcomes in early stages of...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Oxaliplatin based treatments as adjuvant chemotherapy treatment in colon cancer patients

Posted by on Jul 14, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of a 3-month oxaliplatin-based chemotherapy treatment after surgery in patients with stage 3 colon cancer. Researchers suggested 6-months of treatment is associated with better outcomes. Some background The current standard treatment for stage 3 colon cancer patients is surgery followed by...

Read More

Alopecia after breast cancer treatment

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out how common persistent hair loss (alopecia) is after breast cancer chemotherapy, and how to prevent it. The authors found that persistent alopecia was present in all forms of chemotherapy but was worse with docetaxel (Taxotere) and could be prevented by using a scalp cooling technique. Some background...

Read More